MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/72.5/0.1/20.06.25 | Market Closed - Börse Stuttgart 10:14:47 28/06/2024 pm IST | ||
| 1.13 EUR | +1.80% |
|
| Current month | +1.80% | ||
| 1 month | +8.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 1.13 | +1.80% |
| 27/24/27 | 1.11 | -4.31% |
| 26/24/26 | 1.16 | -2.52% |
| 25/24/25 | 1.19 | +2.59% |
| 24/24/24 | 1.16 | +0.87% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 10:14 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME3JA2 |
| ISIN | DE000ME3JA24 |
| Date issued | 13/11/2023 |
| Strike | 72.5 $ |
| Maturity | 20/06/2025 (357 Days) |
| Parity | 10 : 1 |
| Emission price | 0.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.3 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.01 € |
| Spread % | 0.90% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.69%
- Stock Market
- Warrants
- Warrant
